WallStreetZenWallStreetZen

NASDAQ: DAWN
Day One Biopharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DAWN

Based on 5 analysts offering 12 month price targets for Day One Biopharmaceuticals Inc

Min Forecast
$27.00+306.02%
Avg Forecast
$31.20+369.17%
Max Forecast
$36.00+441.35%

Should I buy or sell DAWN stock?

Based on 5 analysts offering ratings for Day One Biopharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DAWN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DAWN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their DAWN stock forecasts and price targets.

DAWN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-07
lockedlocked$00.00+00.00%2025-04-03
lockedlocked$00.00+00.00%2025-03-25
lockedlocked$00.00+00.00%2025-03-05
lockedlocked$00.00+00.00%2025-02-26

1 of 1

Forecast return on equity

Is DAWN forecast to generate an efficient return?

Company
12.79%
Industry
135.39%
Market
89.2%
DAWN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DAWN forecast to generate an efficient return on assets?

Company
11.48%
Industry
46.95%
DAWN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DAWN earnings per share forecast

What is DAWN's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.35
Avg 2 year Forecast
-$0.83
Avg 3 year Forecast
-$0.21

DAWN revenue forecast

What is DAWN's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$146.8M-9.33%
Avg 2 year Forecast
$212.8M+31.39%
Avg 3 year Forecast
$324.0M+100.11%
DAWN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DAWN revenue growth forecast

How is DAWN forecast to perform vs Biotechnology companies and vs the US market?

Company
24.77%
Industry
82.53%
Market
11.03%
DAWN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DAWN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DAWN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DAWN$6.65$31.20+369.17%Strong Buy
EYPT$9.71$25.75+165.19%Strong Buy
DNTH$20.59$52.50+154.98%Strong Buy
AMLX$7.72$12.17+57.71%Strong Buy
KALV$13.21$26.40+99.85%Buy
View Top Biotech Stocks

Day One Biopharmaceuticals Stock Forecast FAQ

Is Day One Biopharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: DAWN) stock is to Strong Buy DAWN stock.

Out of 5 analysts, 2 (40%) are recommending DAWN as a Strong Buy, 3 (60%) are recommending DAWN as a Buy, 0 (0%) are recommending DAWN as a Hold, 0 (0%) are recommending DAWN as a Sell, and 0 (0%) are recommending DAWN as a Strong Sell.

If you're new to stock investing, here's how to buy Day One Biopharmaceuticals stock.

What is DAWN's earnings growth forecast for 2025-2027?

(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.37%.

Day One Biopharmaceuticals's earnings in 2025 is -$69,080,000.On average, 6 Wall Street analysts forecast DAWN's earnings for 2025 to be -$136,839,332, with the lowest DAWN earnings forecast at -$146,975,579, and the highest DAWN earnings forecast at -$126,703,085. On average, 6 Wall Street analysts forecast DAWN's earnings for 2026 to be -$84,303,165, with the lowest DAWN earnings forecast at -$167,248,072, and the highest DAWN earnings forecast at -$15,204,370.

In 2027, DAWN is forecast to generate -$21,620,614 in earnings, with the lowest earnings forecast at -$69,940,103 and the highest earnings forecast at $58,790,231.

What is DAWN's revenue growth forecast for 2025-2027?

(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of 24.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.53%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.03%.

Day One Biopharmaceuticals's revenue in 2025 is $161,922,000.On average, 4 Wall Street analysts forecast DAWN's revenue for 2025 to be $14,882,240,277, with the lowest DAWN revenue forecast at $14,079,246,805, and the highest DAWN revenue forecast at $16,318,343,723. On average, 4 Wall Street analysts forecast DAWN's revenue for 2026 to be $21,565,371,879, with the lowest DAWN revenue forecast at $17,345,145,524, and the highest DAWN revenue forecast at $29,861,383,073.

In 2027, DAWN is forecast to generate $32,844,480,506 in revenue, with the lowest revenue forecast at $25,141,946,563 and the highest revenue forecast at $43,216,901,856.

What is DAWN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: DAWN) forecast ROA is 11.48%, which is lower than the forecast US Biotechnology industry average of 46.95%.

What is DAWN's Price Target?

According to 5 Wall Street analysts that have issued a 1 year DAWN price target, the average DAWN price target is $31.20, with the highest DAWN stock price forecast at $36.00 and the lowest DAWN stock price forecast at $27.00.

On average, Wall Street analysts predict that Day One Biopharmaceuticals's share price could reach $31.20 by May 7, 2026. The average Day One Biopharmaceuticals stock price prediction forecasts a potential upside of 369.17% from the current DAWN share price of $6.65.

What is DAWN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: DAWN) Day One Biopharmaceuticals's current Earnings Per Share (EPS) is -$0.71. On average, analysts forecast that DAWN's EPS will be -$1.35 for 2025, with the lowest EPS forecast at -$1.45, and the highest EPS forecast at -$1.25. On average, analysts forecast that DAWN's EPS will be -$0.83 for 2026, with the lowest EPS forecast at -$1.65, and the highest EPS forecast at -$0.15. In 2027, DAWN's EPS is forecast to hit -$0.21 (min: -$0.69, max: $0.58).

What is DAWN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: DAWN) forecast ROE is 12.79%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.